CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 143 enrolled
Drug / intervention
Stannous Fluoride Dentifrice +1 moreother
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02773758
NCT02773758Phase 4Completed

Short Term Clinical Study Investigating the Efficacy of an Occluding Dentifrice in Providing Relief From Dentinal Hypersensitivity

GlaxoSmithKline·interventional·Posted May 16, 2016·Updated Sep 29, 2017

In Brief

A Phase 4 clinical trial evaluating Stannous Fluoride Dentifrice and Sodium monofluorophosphate Dentifrice for Dentin Sensitivity. Completed, enrolled 143 participants across 1 site.

Detailed Summary

This will be a single centre, two week, randomised, examiner blind, two treatment arm, parallel design, stratified (by maximum baseline Schiff sensitivity score of the two selected test teeth), controlled study, in participant with at least two sensitive teeth that meet the study criteria at the Screening and Baseline visits. The study will be conducted in participants in good general health, with pre-existing self-reported and clinically diagnosed tooth sensitivity at screening.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesCanada
Collaborators--

Timeline

Phase 4CompletedFinished
20162017201820192020202120222023202420252026
First PostedMay 16, 2016
Enrollment StartJan 1, 2016
Primary CompletionMar 11, 2016
TodayJul 2, 2026
Enrollment to primary: 2 monthsPosted 10.1 years ago

Interventions

Stannous Fluoride Dentifriceother

Experimental dentifrice containing 0.454%w/w stannous fluoride (1100ppm fluoride)

Sodium monofluorophosphate Dentifriceother

Dentifrice containing 0.76% w/w sodium monofluorophosphate (1000ppm fluoride)